Interim trial data suggest a safer way to target Alzheimer’s could reshape the next generation of therapies.
The race to treat Alzheimer’s disease has followed one dominant idea: destroy the amyloid plaques that build up in the brain. That strategy has finally delivered approved medicines, but it has also come with an uncomfortable compromise. Many patients require frequent MRI scans because the same drugs can trigger amyloid-related imaging abnormalities (ARIA), including potentially dangerous brain swelling.
What if the industry has been aiming at the wrong target all along?
That question is becoming harder to ignore after ProMIS Neurosciences reported positive six-month interim data from its Phase 1b PRECISE-AD trial of PMN310 [1]. Instead of attacking large amyloid plaques, PMN310 is designed to seek out only the smaller, toxic amyloid oligomers that scientists increasingly believe are among the earliest troublemakers in Alzheimer’s disease.
The early results raise another intriguing question. Current anti-amyloid therapies carry their greatest risks for people who inherit two copies of the APOE4 gene – a group that has historically faced some of the hardest treatment decisions. Yet in ProMIS’ trial, which included 61% APOE4 carriers, including 11% with two copies of the gene, no cases of ARIA-E were reported.
The trial remains blinded, meaning researchers still do not know which participants received PMN310 and which received placebo. But if the final data support these early findings, they could point to more than another Alzheimer’s drug – they could signal a shift in what future Alzheimer’s therapies are expected to achieve.
Changing the target, not just the treatment
Imagine cleaning up a city after a storm. Most current Alzheimer’s therapies focus on removing the piles of debris left behind. PMN310, by contrast, is designed to stop the loose, fast-moving fragments causing the damage before they accumulate into larger piles.
Researchers increasingly suspect that these soluble amyloid oligomers are among the earliest and most toxic forms of the protein. By selectively binding to them while avoiding the larger plaques, PMN310 aims to interrupt the disease process without disturbing brain tissue in ways that may contribute to ARIA.
In the interim analysis of 136 participants with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s disease, the company reported no cases of ARIA-E. A small number of participants experienced mild, symptom-free microbleeds, known as ARIA-H, which ProMIS said tracked expected background rates. There were also no treatment-related serious adverse events or drug-related discontinuations.
Encouraging signals, but not the final answer
Beyond safety, researchers also reported early movement in two biomarkers commonly used to monitor Alzheimer’s biology. Most participants showed reductions rather than the increases typically seen as the disease progresses. That does not mean the drug has been proven to slow Alzheimer’s.
Think of biomarkers as the dashboard lights on a car. If a warning light switches off, it suggests something under the hood may be improving, but it does not tell you how well the car will perform over the next hundred miles.
Because the study remains blinded, these biomarker changes cannot yet be linked directly to PMN310, and they should not be interpreted as evidence of clinical benefit. The real test will come when researchers compare treated patients with those who received placebo after the trial is completed.
“The absence of ARIA-E, an overall favorable safety profile, and early biomarker movement together align with our expectations based on our prior studies. We look forward to our 12-month topline readout in the first quarter of 2027,” said Neil Warma, CEO of ProMIS Neurosciences.
Dr Will Mantyh, a behavioral neurologist at the University of Minnesota, believes safety could ultimately determine whether therapies reach more patients.
“In real-world practice, ARIA risk is the central prescribing barrier: clinicians, patients, and health systems must contend with the issues of safety monitoring, identification, and sometimes emergent neurological treatment of ARIA,” he said. “A profile with low incidence of total ARIA, including no ARIA-E, would be a game-changer. Just as importantly, plasma pTau217 and CSF MTBR-tau243 are among the most informative fluid biomarkers we have for tracking Alzheimer’s biology; seeing early, coherent movement in both is highly encouraging before a definitive readout.”
A new benchmark for longevity?
Topline 12-month results are expected in the first quarter of 2027, when researchers will finally learn whether PMN310 can translate these encouraging biological signals into meaningful clinical benefits.
Regardless of the outcome, the conversation around Alzheimer’s is already evolving. The next generation of therapies may no longer be judged simply by how effectively they remove amyloid, but by how intelligently they target it. If a treatment can preserve the potential benefits of anti-amyloid therapy while dramatically reducing its risks, the definition of success itself begins to change.
That matters far beyond neuroscience. Alzheimer’s remains one of the greatest obstacles to healthy longevity, robbing people not only of years but of independence, identity and quality of life. Extending healthspan will require therapies that patients can realistically access and physicians can confidently prescribe.
Is the era of simply blasting away plaques beginning to give way to a more selective, precision-driven approach? And could APOE4 carriers, long considered the patients with the fewest safe options, become the first to benefit from that shift? The answers will not arrive until the trial is unblinded next year, but if PMN310 continues on its current trajectory, it may be remembered less as another Alzheimer’s antibody and more as the therapy that challenged the field’s assumptions about where the real target was all along.
